Introduction
============

Since Trounson and Mohr \[[@B1]\] reported the first successful pregnancy achieved via frozen-thawed embryo transfer (FET) in 1983, embryo cryopreservation has become an integral part of assisted reproductive technology (ART) programs. Compared with oocyte collection via repeated "fresh" cycles, FET is a relatively simple procedure that increases the cumulative pregnancy rate and reduces procedural time and costs \[[@B2]\]. FET enables the transfer of a good-quality single embryo after a given oocyte aspiration cycle, thus preventing both multifetal gestations and ovarian hyperstimulation syndrome, and facilitates delayed embryo transfer if the endometrial preparation is not optimal \[[@B3][@B4]\].

In almost all ART centers, the pregnancy rates after FET are reported to be lower than those after fresh embryo transfer \[[@B5]\]. This is because 1) the best embryos are usually selected for embryo transfer in fresh ART, and 2) the process of embryo freezing and thawing is associated with ice crystal formation, which can reduce embryo quality \[[@B6][@B7][@B8]\]. Advances in embryo cryopreservation techniques, such as embryo vitrification with high condensation of cryoprotectants, in which minor intracellular ice crystal formation occurs and reduces cellular lesions, are associated with 90--100% embryo survival rates after warming and an increased live birth rate (LBR) \[[@B9]\]. Nevertheless, exact synchronization between endometrial maturation and embryo development remains essential \[[@B10]\].

FET is performed using various cycle regimens: spontaneous ovulatory (natural) cycles, cycles in which ovulation is induced by drugs, cycles in which the endometrium is artificially prepared by using hormonal substitution with estrogen (E2) and progesterone (P4), and hormone therapy (HT) FET cycles. HT FET cycles can be used with or without a gonadotropin-releasing hormone agonist (GnRHa) for pituitary suppression. There are a number of studies comparing natural FET cycles and HT FET cycles; however, their results have been conflicting. Kawamura et al. \[[@B11]\] showed that pregnancy outcomes were and between HT FET cycles and natural FET cycles. Some studies reported comparable outcomes for natural FET cycles and HT FET with GnRHa cycles \[[@B12][@B13]\]. Other studies reported that natural FET cycles had better outcomes than HT FET cycles \[[@B14][@B15]\]. By contrast, Hill et al. \[[@B16]\] suggested that HT FET cycles result in higher LBRs than those of natural FET cycles for blastocyst-stage embryo. Indeed, in a recent Cochrane review based on 7 randomized controlled trials comparing different cycle regimens for FET, it was concluded that no regimen was superior to another regimen \[[@B17]\].

Therefore, we aimed to evaluate 3 different treatment groups based on our regular protocols (artificial preparation of the endometrium by using a combination of E2 and P4 hormones with a GnRHa, a combination of E2 and P4 hormones without a GnRHa, and the modified natural cycle \[MNC\] with the use of human chorionic gonadotropin \[hCG\] trigger with P4), which led to different pregnancy outcomes.

Materials and methods
=====================

This was a retrospective study conducted at Wonju Severance Christian Hospital Infertility Center. Women undergoing FET were considered eligible for the study if they exhibited a regular menstrual cycle (length 24--35 days), were 21--45 years of age, and had previous *in vitro* fertilization cycles with embryo cryopreservation. We performed the 3 endometrial preparation protocols according to the patients\' age, ovarian reserve and preferences. The exclusion criteria were polycystic ovarian syndrome according to Rotterdam criteria \[[@B18]\], a FET after preimplantation genetic diagnosis, oocytes donation, the history of uterine synechiae, and endometriosis stage IV.

1. Endometrial preparation protocols {#sec1}
------------------------------------

### 1) Group A: HT with GnRHa

In the patients of group A, after an ultrasound assessment between days 10 and 13 before the FET cycle to confirm follicular development, and when ovulation was identified, 0.5 mg/day of the GnRHa buserelin acetate (Suprefact^®^; Sanofi-Aventis, Seoul, Korea) was administered via subcutaneous depot injection from the midluteal phase (day 21) for 2 weeks. On the first day of menstruation, the patients were started on oral estradiol valerate (Progynova^®^; Bayer Schering Pharma AG, Berlin, Germany) at a daily dosage of 2 mg from day 1 to 2, 4 mg from day 3 to 10, 8 mg from day 11 to 14, and 4 mg from day 15 to the day of the pregnancy test. A serial transvaginal ultrasound was performed after 11--13 days of estrogen treatment. If there was no dominant follicle nor signs of ovulation, and endometrial thickness reached at least 7 mm, FET was scheduled. If the endometrial preparation was inadequate, it was continued and monitoring ultrasound scans were taken to confirm further endometrial growth. Progesterone in oil was intramuscularly (IM) administered at a dose of 50 mg/day before embryo transfer, depending on the cleavage stage of embryos (embryo age+1 day). E2 and P4 supplementation was continued if pregnancy was confirmed, until 12 weeks of pregnancy.

### 2) Group B: HT without GnRHa

In the patients of group B, treatment was initiated without prior pituitary suppression. After spontaneous menstruation, endometrial preparation was initiated with oral estradiol valerate (Progynova^®^), which was increased, in a step-up protocol, to 8 mg/day in the same way as in group A. An ultrasound was performed 11--13 days later if the endometrial thickness was ≥7 mm and there was no dominant follicle. Luteal support commenced at 4 or 6 days before FET (embryo age+1 day) through IM injection of progesterone 50 mg daily until pregnancy testing. If the pregnancy test result was positive, HT (E2+P4) was continued for a further 6 weeks.

### 3) Group C: MNC (natural cycle with the use of hCG trigger) with P4

The patients of group C (MNC with P4) underwent a transvaginal ultrasound on day 3 and on days 10--12 of the menstrual cycle. Follicular growth was monitored through serum hormonal analysis and regular ultrasound assessment. hCG (Ovidrel^®^ 250 μg; Merck Serono SA, Geneva, Switzerland) was administered subcutaneously when the leading follicle reached a mean diameter of ≥17 mm and the endometrial thickness was ≥7 mm. The day of ovulation was calculated at 36--40 hours after hCG administration. The timing of FET was based on the day of embryo freezing and on the day of hCG injection (i.e., 5 days for day 3 embryos and 7 days for day 5 blastocysts). Progesterone supplementation (IM progesterone 50 mg/day) was conducted from 2 days after hCG injection to 12 weeks of pregnancy.

2. Embryo transfer and outcomes {#sec2}
-------------------------------

Embryo transfer was performed in the same way in the 3 groups. One or two frozen--thawed embryos were transferred at 1--2 cm below the fundus of the uterine cavity, following the protocol of our infertility center (i.e., standard procedures with abdominal ultrasound guidance, according to the patients\' age and preferences). A Cook Guardia™ AccessET curved embryo transfer catheter (K-JETS-6019-ET) was used, and embryo transfer was performed with only viable, top-quality, high-grade embryos.

The serum β-hCG level was measured at 12--14 days after the FET. If the pregnancy test was positive (serum β-hCG \>25 mIU/mL), transvaginal ultrasound was performed 2 weeks later to determine the number of gestational sacs and fetal viability. The primary outcome was the implantation rate (IR), defined as presence of an intrauterine or extrauterine gestational sac on ultrasound, per embryo transferred. The secondary outcomes included the biochemical pregnancy rate (defined as a positive pregnancy test), clinical pregnancy rate (CPR, defined as the presence of a gestational sac with an embryo with a positive heartbeat at 6--8 weeks of gestation), ongoing pregnancy rate (defined as at least one viable fetus beyond gestation week 12 on ultrasound), miscarriage rate (defined as pregnancy loss until 12 weeks of gestation after a previous clinical confirmation of pregnancy), LBR (defined as the delivery of at least one live-born baby beyond 24 weeks of gestation), and preterm delivery (defined as the delivery of a baby before the gestational age of 37 weeks). Birth outcome data were collected from the patients.

3. Statistical analysis {#sec3}
-----------------------

Student\'s *t*-test, χ^2^ analysis, and one-way analysis of variance were used where appropriate. The results are presented as mean±standard deviation, and *P*\<0.05 was considered statistically significant. Statistical analysis was performed using SPSS 24.0 (IBM, Armonk, NY, USA).

Results
=======

This was a retrospective study that evaluated 187 patients during a 3-year period (February 2012--April 2015). The patients were allocated to 3 treatment groups, as follows: group A, comprising 113 patients (181 cycles) who received HT with GnRHa; group B, comprising 49 patients (88 cycles) who received HT without GnRHa; and group C, comprising 25 patients (42 cycles) who received hCG+P4.

The patients\' baseline characteristics are described in [Table 1](#T1){ref-type="table"}. There was no significant difference among the 3 groups in demographic characteristics such as age and body mass index. The etiologies of infertility, which included male factor, diminished ovarian reserve, tubal factor, unexplained, and others, were similar among the 3 treatment groups ([Table 1](#T1){ref-type="table"}). No significant differences were detected among the 3 groups in the previous fresh cycles, mean duration of infertility, duration of cryopreservation, embryo survival, developmental stage of cryopreservation, mean number of embryos transferred, total number of embryos transferred, and endometrial thickness ([Table 1](#T1){ref-type="table"}). This suggests that the 3 groups had similar pregnancy potential. No cycle was cancelled in all 3 groups because of ovulation, zero embryo survival, or failure of the endometrium to reach a thickness of at least 7 mm.

###### Baseline characteristics

![](ogs-61-489-i001)

  Variables                                 Type of endometrial preparation                                   
  ----------------------------------------- --------------------------------- ---------------- -------------- --------------
  No. of patients                           113                               49               25             
  Age (yr)                                  37.9±7.6                          36.5±6.6         37.1±4.4       
  BMI (kg/m^2^)                             21.6±3.1                          20.0±4.1         23.6±6.3       
  Previous fresh cycles                     2.4 (1--7)                        2.0 (1--6)       3.3 (1--6)     
  Previous FET cycles                       2.1 (0--4)                        2.2 (0--4)       1.8 (0--4)     
  Mean duration of infertility (mon)        54.3±32.2                         45.4±24.5        46.2±33.5      
  Etiology of infertility                                                                                     
                                            Male factor                       20/113 (17.7)    9/49 (18.4)    6/25 (24.0)
                                            Diminished ovarian reserve        37/113 (32.7)    18/49 (36.7)   3/25 (12.0)
                                            Tubal factor                      14/113 (12.4)    7/49 (14.3)    5/25 (20.0)
                                            Unexplained                       15/113 (13.3)    5/49 (10.2)    7/25 (28.0)
                                            Others                            27/113 (23.9)    10/49 (20.4)   4/25 (16.0)
  Duration of cryopreservation (mon)        37.8                              38.5             31.6           
  Embryo survival (%)                       92.0                              92.6             93.3           
  Developmental stage of cryopreservation                                                                     
                                            Cleavage stage (day 3 or 4)       160/181 (88.4)   80/88 (90.9)   36/42 (85.7)
                                            Blastocyst stage (day 5)          21/181 (11.6)    8/88 (9.1)     6/42 (14.3)
  Mean No. of embryos transferred           1.6                               1.8              1.7            
  Total No. of embryos transferred          181                               88               42             
  Endometrial thickness (mm)                9.0±2.8                           8.0±1.6          8.4±2.0        

Data are shown as mean±standard deviation, number (%) or number (range).

HT, hormone therapy; GnRHa, gonadotropin-releasing hormone agonist; MNC, modified natural cycle; P4, progesterone; BMI, body mass index; FET, frozen--thawed embryo transfer.

The clinical results of FET are presented in [Table 2](#T2){ref-type="table"}. The results of the present study revealed that the primary outcome of the study --- the IR per embryo transferred --- was not statistically different among the 3 groups (76/181 \[42.0%\] in group A vs. 24/88 \[27.3%\] in group B vs. 16/42 \[38.1%\] in group C, *P*\>0.05). Similar results were found for the IRs with fetal heartbeat per embryo transferred (68/181 \[37.6%\] in group A vs. 22/88 \[25.0%\] in group B vs. 14/42 \[33.3%\] in group C, *P*\>0.05) and for the LBRs per embryo transferred (56/181 \[30.9%\] in group A vs. 18/88 \[20.5%\] in group B vs. 11/42 \[26.2%\] in group C, *P*\>0.05). The 3 groups were comparable with respect to reproductive outcome per embryo transfer cycle. There were no statistically significant differences in the CPR, CPR with fetal heartbeat, miscarriage rate, and LBR.

###### Clinical results of frozen--thawed embryo transfer
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  Variables                                        Type of endometrial preparation                                   
  ------------------------------------------------ ---------------------------------- --------------- -------------- --------------
  Reproductive outcome per embryo transferred                                                                        
                                                   Total no. of embryos transferred   181             88             42
                                                   Implantation rate (IU+EU)^a)^      76/181 (42.0)   24/88 (27.3)   16/42 (38.1)
                                                   Implantation rate with FHB         68/181 (37.6)   22/88 (25.0)   14/42 (33.3)
                                                   Miscarriage rate^b)^               10/68 (14.7)    4/22 (18.2)    3/14 (21.4)
                                                   Live birth rate^c)^                56/181 (30.9)   18/88 (20.5)   11/42 (26.2)
  Reproductive outcome per embryo transfer cycle   113                                49              25             
                                                   Clinical pregnancy rate (IU+EU)    59/113 (52.2)   21/49 (42.9)   12/25 (48.0)
                                                   Clinical pregnancy rate with FHB   55/113 (48.7)   20/49 (40.8)   12/25 (48.0)
                                                   Miscarriage rate                   7/55 (12.7)     4/20 (20.0)    3/12 (12.0)
                                                   Live birth rate                    47/113 (41.6)   16/49 (32.7)   9/25 (36.0)

Data are shown as mean±standard deviation or number (%).

HT, hormone therapy; GnRHa, gonadotropin-releasing hormone agonist; MNC, modified natural cycle; P4, progesterone; IU, intrauterine; EU, extrauterine; FHB, fetal heartbeat.

^a)^Presence of an intrauterine or extrauterine gestational sac; ^b)^Pregnancy loss until 12 weeks after a previous clinical confirmation of pregnancy on ultrasound; ^c)^Live birth of a child beyond 24 weeks of gestation.

The obstetric outcomes are shown in [Table 3](#T3){ref-type="table"}. A total of 73 ongoing pregnancies were confirmed. In group A, 38 of 48 were singleton pregnancies, 8 of 48 were twin pregnancies, and 2 of 48 were triple pregnancies (1 triple pregnancy was excluded because of second-trimester termination owing to an incompetent internal os of the cervix). In group B, 14 of 16 were singleton pregnancies, 1 of 16 was a twin pregnancy, and 1 of 16 was a triple pregnancy. In group C, 7 of 11 were singleton pregnancies and 2 of 11 were twin pregnancies. The percentages of vaginal delivery and cesarean section in singleton pregnancies were similar among the 3 groups. All twin and triple pregnancies were delivered via cesarean section. The fetal weight at delivery was also comparable among the 3 groups. Overall, no adverse events and hospitalizations were reported. In our observed obstetric outcome, 11 dichorial diamniotic twin pregnancies (8 in group A, 1 in group B, and 2 in group C) and 2 triple pregnancies (monochorial diamniotic+singleton) were found in each of groups A and B. None of the newborns had congenital malformations.

###### Obstetric outcomes
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  Variables                            Type of endometrial preparation                                      
  ------------------------------------ --------------------------------- ----------------- ---------------- ---------------
  Ongoing pregnancies^a)^              48                                16                9                
  Live birth rate^b)^                  56                                18                11               
  Singleton ongoing pregnancies        38/48 (79.2)                      14/16 (87.5)      7/9 (77.8)       
                                       Vaginal delivery                  23/38 (60.5)      9/14 (64.3)      4/7 (57.1)
                                       Cesarean section                  15/38 (39.5)      5/14 (35.7)      3/7 (42.9)
                                       Preterm delivery                  1                 1                1
                                       Fetal weight (g)                  2,936.4±452.2     3,274.1±392.5    2,819.6±269.0
  Twin or triple ongoing pregnancies   9^c)^/48 (18.8)                   2^d)^/16 (12.5)   2^e)^/9 (22.2)   
                                       Preterm delivery                  5                 1                0
                                       Fetal weight (g)                  1,910.2±725.0     1,966.9±558.1    2,502.3±324.3

Data are shown as mean±standard deviation or number (%).

HT, hormone therapy; GnRHa, gonadotropin-releasing hormone agonist; MNC, modified natural cycle; P4, progesterone.

^a)^Viable pregnancy with fetal heartbeat at 12 weeks of gestational age; ^b)^Live birth of an infant beyond 24 weeks of gestation; ^c)^One ongoing triple pregnancy was excluded because of second-trimester termination owing to an incompetent internal os of the cervix (eight twin+one triple pregnancies); ^d)^One twin+one triple pregnancies; ^e)^Two twin pregnancies.

Discussion
==========

This study suggests that HT with or without GnRHa and MNC with P4 result in similar IRs, CPRs, and LBRs. These findings indicate that endometrial preparation with HT without GnRHa does not decrease the success rate of FET. This is consistent with the results of several previous studies. For example, in a retrospective comparison of 417 women with regular menstrual cycles undergoing HT FET with GnRHa versus natural cycles, there was no difference in IRs, CPRs, and LBRs \[[@B12]\]. Similarly, in a prospective randomized study comparing endometrial preparation with and without previous GnRHa, E2 was administered at a dose of 6 mg/day to women not treated with GnRHa and at 4 mg/day to women with previous GnRHa. That trial reported the successful use of E2 and P4 without previous ovarian suppression with GnRHa in women with functioning ovaries who were undergoing FET \[[@B19]\]. This was also seen in the report of Dal Prato et al. \[[@B20]\]. In the most recently published systematic review and meta-analysis on the most effective method of endometrial preparation before FET, it was also concluded that is not possible to identify one method of endometrium preparation in FET as being superior over another \[[@B21]\].

Embryo implantation is the most critical step in ART, and is determined by the direct and linear interaction of 3 primary factors that are integral to the physiological process: endometrial competence with adequate P4 priming, viable embryo, and a synchronized dialogue between the endometrium and the preimplantation embryo \[[@B22]\]. Ovarian steroids such E2 and P4 play crucial roles in endometrial receptivity, blastocyst implantation, and maintenance of pregnancy \[[@B22]\]. In the past, the most popular protocol was endometrial preparation with exogenous E2 and P4 after pituitary downregulation with a GnRHa, to avoid spontaneous ovulation. The main advantage of such a protocol is that the risk of cycle cancellation can be drastically reduced by the GnRHa used to prevent premature endometrial luteinization. Moreover, the date of embryo thawing and transfer can be selected by the medical staff or the patient, thus minimizing the related cycle monitoring procedures (i.e., hormonal analyses and ultrasound scans of the endometrium) as well as the patient anxiety. However, the protocol has disadvantages, including the high cost of the GnRHa, patient inconvenience, risk of hypoestrogenic adverse effects before hormonal replacement, adverse effects of E2 supplementation (e.g., increased thrombotic risk), and prolonged treatment (especially in the case of pregnancy) \[[@B23]\]. Therefore, an HT FET with GnRHa cycle is a more flexible and convenient protocol for patients with irregular cycles, and it achieved similar results to those of other endometrial preparation protocols used in women with regular cycles. In fact, this study at our center also suggested higher IRs, CPRs, and LBRs after HT FET with GnRHa cycles than after HT FET without GnRHa or after MNC with P4, although there were no statistically significant differences.

This study has certain limitations. First, this retrospective study could not investigate other potential confounders, including ovulation protocol, supplementation agent for implantation (embryo glue, aspirin, intralipid, Tractocile, immunoglobulin, etc.), and social habits (diet, nutritional supplements, exercise, etc.), that may affect the FET results. Second, we analyzed only limited perinatal outcomes, including type of delivery, preterm delivery, and fetal weight on delivery, and some of the data were self-reported by the patients. Third, the sample size was too small to reach definite conclusions. Nevertheless, our findings highlight the importance of estimating perinatal outcomes in women undergoing FET, and provide comparable data among 3 treatment groups. Furthermore, relatively high IRs, CPRs, and LBRs were recorded. This may be because of several reasons. (i) We used only high-grade, top-quality embryos for FET. (ii) Although the use of luteal support is still controversial, it is a standard practice at our fertility center, supported by the results of a retrospective study and a randomized controlled trial \[[@B24][@B25]\]. Recently, Kim et al. \[[@B26]\] showed that during natural FET, luteal phase support with P4 supplementation decreased miscarriage rate and improved the LBR. (iii) We used only the vitrification method for frozen embryo thawing. (iv) No participants withdrew from the study or had their cycle cancelled because of spontaneous ovulation, endometrial thickness \<7 mm, or failure to thaw the embryo. When the pituitary gland is not suppressed with a GnRHa, it is important to start E2 in the early follicular phase (on day 1 or 2). With this approach, although initial follicular activity is sometimes present, spontaneous ovulation seems to be inhibited. Starting E2 after day 3 of the cycle might lead to an increased incidence of luteinizing hormone surge and luteinization of the endometrium \[[@B27]\].

In conclusions, the results of the present study suggest that HT FET with GnRHa, HT FET without GnRHa, or MNC with P4 FET in patients with regular menstruation may be good options with no adverse effects on cycle outcome. However, the study lacked sufficient statistical power to reach definitive conclusions about the comparability of the 3 studied interventions. Therefore, additional double-blinded, randomized controlled trials with increased resolving power are required in the future to more accurately evaluate the efficacy of each treatment regimen.
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